Discussions with leaders: JNM editor-in-chief Johannes Czernin, with Caius Radu, continues a series of interviews with leaders in nuclear and molecular imaging and therapy with a conversation with Antoni Ribas, MD, PhD, about advancing cancer research and treatment.
Page 1178
Image-guided HIFU in nuclear medicine: Zhang and colleagues present a state-of-the-art review of the principles and clinical applications of image-guided high-intensity focused ultrasound, including examples of future potential development.
Page 1181
Cardiac PET and the future: Di Carli offers perspective on the changing epidemiology and pathobiology of coronary artery disease, the efficacy of conventional imaging tools, and the advantages of quantitative PET as a transformative modality in nuclear cardiology.
Page 1189
Pheochromocytoma and paraganglioma: Carrasquillo and colleagues provide an educational overview of the clinical features of pheochromocytoma and paraganglioma, as well as therapeutic strategies with 131I-MIBG and 90Y- or 177Lu-DOTA-somatostatin analogs.
Page 1192
Current clinical pretargeting: Jallinoja and Houghton survey the recent history of pretargeting radioimmunoimaging and therapy studies, challenges faced in human studies and regulatory approval, and future avenues for clinical translation.
Page 1200
Diversity in nuclear medicine: Cheng and colleagues report on the results of a study designed to characterize the status in nuclear medicine of women and racial/ethnic groups underrepresented in medicine in the United States.
Page 1207
18F-FES PET for clinical dilemmas: Boers and colleagues present findings from a retrospective study of the utility of 18F-FES PET imaging in resolving questions in breast cancer after standard workups.
Page 1214
Pretargeted immuno-PET in MTC: Bodet-Milin and colleagues describe the results of analyses to determine the sensitivity of anti–carcinoembryonic antigen immuno-PET in relapsing medullary thyroid carcinoma and compare these with conventional imaging and 18F-DOPA PET/CT.
Page 1221
68Ga-BMS-986192 for PD-L1 PET: Robu and colleagues detail the development and preclinical evaluation of a 68Ga-labeled adnectin protein to facilitate imaging of PD-L1 expression in tumors.
Page 1228
PSMA PET for HCC: Hirmas and colleagues assess the effects of 68Ga-prostate-specific membrane antigen-11 PET/CT neovasculature imaging on disease staging, prognostics, and management of patients with hepatocellular carcinoma.
Page 1235
Expanding PSMA theranostics: Brenner and colleagues offer perspective on the potential for nonprostatic applications of prostate-specific membrane antigen–based theranostics, particularly in tumors with high need for therapy improvement.
Page 1242
MSG and 68Ga-PSMA PET/CT: Armstrong and colleagues use 68Ga-PSMA-11 PET to determine the effect of monosodium glutamate administration on prostate-specific membrane antigen–radioligand biodistribution in healthy organs and tumor lesions in men with prostate cancer.
Page 1244
Diuresis and dual-time-point PSMA PET: Alberts and colleagues investigate a modified prostate-specific membrane antigen PET/CT protocol combining late additional imaging with hydration and forced diuresis in assessment for uncertain findings.
Page 1252
68Ga-PSMA PET/CT versus nano-MRI: Schilham and colleagues compare characteristics of prostate-specific membrane antigen PET/CT and ferumoxtran-10 nanoparticle–enhanced MRI to determine the feasibility of their complementary use for prostate cancer imaging.
Page 1258
SUV and TBR in 18F-DCFPyL PET/CT: Bodar and colleagues explore whether SUV on PET/CT, as compared with tumor-to-blood ratio, can provide adequate quantification of uptake of this ligand in a patient cohort with low prostate cancer burden.
Page 1264
PSMA PET and bipolar androgen therapy: Markowski and colleagues analyze the utility of 18F-DCFPyL PET/CT in determining clinical response to this emerging treatment for metastatic castration-resistant prostate cancer.
Page 1270
PRRT plus 131I-MIBG: Bushnell and colleagues report on preliminary results of a study on the addition of 131I-MIBG to 90Y-DOTATOC peptide-receptor radionuclide therapy for progressive metastatic neuroendocrine tumors.
Page 1274
NETPET score in lung NENs: Chan and colleagues describe evaluation of this prognostic score, combining 18F-FDG and somatostatin receptor imaging agent uptake data, in bronchial neuroendocrine neoplasms.
Page 1278
18F-FCH PET metaanalysis: Whitman and colleagues summarize data on the sensitivities and specificities of 18F-FCH PET in localizing hyperparathyroidism and compare these results with those from comparable 99mTc-sestamibi scans.
Page 1285
TauIQ algorithm: Whittington and Gunn report on development of a PET data quantification algorithm for the complex spatial distribution of tau radiotracers, with specific promise in longitudinal analyses and early detection of tau deposition.
Page 1292
Hypermetabolism on brain 18F-FDG PET: Chugani discusses and provides examples of the multiple causes of hypermetabolism on 18F-FDG PET studies that should not be interpreted as seizure activity.
Page 1301
D1R PET tracers: Barret and colleagues characterize in nonhuman primates 2 novel D1 receptor agonist PET radiotracers, racemic 18F-MNI-800 and its more active atropisomeric (−)-enantiomer, 18F-MNI-968.
Page 1307
Enhancing robot-assisted radioguided surgery: Azargoshasb and colleagues describe development of a real-time fluorescence-video–based tracking method that integrates the DROP-IN γ-probe with navigated robotic surgery.
Page 1314
Advanced imaging for primary lateral sclerosis: Masrori and colleagues present results from work-up imaging with MRI, 123I-FP-CIT PET, 18F-PE2I PET, and 18F-FDG PET in a patient with unilateral mild paresis, slowing of the upper limb, and parkinsonism.
Page 1318
- © 2021 by the Society of Nuclear Medicine and Molecular Imaging.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.